The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy
NCT02573636
·
clinicaltrials.gov ↗
RECRUITING
Status
208
Enrollment
OTHER
Sponsor class
Conditions
Prostate Cancer
Sponsor
Sir Mortimer B. Davis - Jewish General Hospital